PR90450

LACHEN, Switzerland, July 5, 2021 /PRNewswire=KYODO JBN/ --

Octapharma announced today that new clinical and scientific findings

encompassing their Haematology portfolio, including Nuwiq(R), wilate(R),

octanate(R) and octanine(R)F, will be presented at the upcoming International

Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on

July 17–21, 2021.

In addition to two Supported Symposia that will discuss the comprehensive

management of patients with haemophilia A and von Willebrand disease, seven

ePosters will be presented covering a broad range of clinical research and

ongoing initiatives to support the bleeding disorder community.

"Every day, our patients inspire us with their strength and resilience in

navigating the challenges of living with a bleeding disorder. We are proud to

share our most recent findings at ISTH 2021. The breadth of positive data

across our Haematology portfolio demonstrate our ongoing efforts in addressing

the differing unmet needs of patients with haemophilia and von Willebrand

disease," commented Larisa Belyanskaya, Head of IBU Haematology at Octapharma.

The symposium on von Willebrand disease, that takes place on Monday, July 19,

chaired by Dr Fernando F. Corrales-Medina, follows one woman's treatment

journey with wilate(R) and will highlight key unmet needs of people who live

with this challenging bleeding disorder. The international faculty will present

and discuss recent data and ongoing studies on the management of heavy

menstrual bleeding, pregnancy and childbirth, as well as management of

perioperative bleeding in people with VWD.

On Tuesday, July 20, Dr Robert F. Sidonio Jr. will chair Octapharma's symposium

on haemophilia A, in which experts from around the world will present both

clinical and scientific data from global collaborations on inhibitor

management, factor VIII prophylaxis and important roles of factor VIII beyond

haemostasis, aiming to support clinicians in making informed treatment

decisions.

Attendees will have the opportunity in both symposia to meet the speakers

during live Q&A sessions, and both symposia will be available on-demand to

participants after the Congress.

Olaf Walter, Board Member at Octapharma, stated that: "At Octapharma, we strive

toward addressing the substantial challenges faced by people with bleeding

disorders and to improve the lives of these individuals and their families.

ISTH is an invaluable forum for engagement with key opinion leaders, experts,

and the wider bleeding disorder community, and for sharing our expertise and

research. Our contributions to ISTH 2021 underlie our long-standing commitment

to every member of the bleeding disorder community."

Supported Symposia

From Clinical Insights to Patient Experience: Suzanne's Journey with von

Willebrand Disease

Monday 19 July, 12:30–13:30 (EDT)

Chair: Dr Fernando F. Corrales-Medina, Division of Pediatric

Hematology-Oncology, University of Miami-Miller School of Medicine, Miami, USA

Factor in the Future: Informed Treatment Decisions for Haemostasis and Beyond

Tuesday 20 July, 12:30–13:30 (EDT)

Chair: Dr Robert F. Sidonio Jr., Hemophilia of Georgia Center for Bleeding and

Clotting Disorders, Children's Healthcare of Atlanta, Emory University,

Atlanta, USA

ePosters

PB0502: Prospective, open-label, multicentre phase II study (PeKaFIX) to

evaluate the pharmacokinetic parameters of a plasma derived factor IX

concentrate and build a pharmacokinetic Bayesian model

PB0535: Long-term prophylaxis with simoctocog alfa in children

PB0549: Immunogenicity and safety of simoctocog alfa in previously treated

patients switching to simoctocog alfa in the GENA clinical trial programme

PB0590: Efficacy of simoctocog alfa in previously untreated patients with

severe haemophilia A: Final results from the NuProtect study

PB0627: PRactical Utilisation of Octapharma FVIII Concentrates in Previously

Untreated and Minimally Treated Haemophilia A Patients Entering Routine

Clinical Treatment with Nuwiq(R), octanate(R) or wilate(R) – The Protect-NOW

Study

PB0939: Plasma-derived VWF/FVIII concentrate (wilate(R)) for haemostasis in

women with VWD during childbirth

PB0926: Don't Let Bleeding Go Unnoticed – A Global Initiative to Increase

Awareness of von Willebrand Disease

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human

protein manufacturers in the world, developing and producing human proteins

from human plasma and human cell lines.

Octapharma employs more than 9,000 people worldwide to support the treatment of

patients in 118 countries with products across three therapeutic areas:

Immunotherapy, Haematology, and Critical Care.

Octapharma has seven R&D sites and six state-of-the-art manufacturing

facilities in Austria, France, Germany, Mexico and Sweden, and operates more

than 160 plasma donation centres across Europe and the US.

For more information, please visit: www.octapharma.com.

Logo - https://mma.prnewswire.com/media/1556893/Octapharma_Logo.jpg

SOURCE: Octapharma